Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

- test


PARP inhibitors and immunotherapy agents continue to be investigated in the field of metastatic castration-resistant prostate cancer (mCRPC), and a... Read More

Novel Imaging Techniques Advancing Prostate Cancer Care

maging agents for patients with prostate cancer continue to receive FDA approvals, according to William R. Berry, MD. For example,... Read More

PSMA-PET Agents Poised to Advance Imaging in Prostate Cancer

Imaging agents for the detection of biochemical recurrent prostate cancer could move beyond computed tomography (CT) and magnetic resonance imaging... Read More

Use of Active Surveillance Increasing for Low-Risk Prostate Cancer

The utilization of active surveillance and prostate-specific antigen (PSA) screening has continued to shift in the recent years, particularly following... Read More

FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

A supplemental new drug application has been submitted for abiraterone acetate (Zytiga) in combination with prednisone and androgen deprivation therapy... Read More

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving... Read More

Testing Picture Is Coming Into Sharper Focus for Familial and Hereditary Prostate Cancer

Research into the biology of prostate cancer has resulted in a growing understanding of the molecular drivers of the malignancy,... Read More

Novel Imaging Agent May Improve Prostate Cancer Detection

An investigational radiotracer that targets prostate-specific membrane antigen (PSMA) is being tested in patients with high-risk, recurrent, or metastatic prostate... Read More

Researchers Aim to Further Enhance Value of RT in Prostate Cancer

Researchers have long debated whether surgery or radiation therapy (RT) is a more beneficial treatment method for locally advanced prostate... Read More

Combinations Key to Advances With Bone-Targeting Agents in mCRPC

Radium-223 dichloride (Xofigo) remains the sole radiopharmaceutical that benefits patients with metastatic castration-resistant prostate cancer (mCRPC) from both a skeletal-related... Read More

1 2